The global market for G-Protein Coupled Receptors (GPCRs) is estimated at US$3.4 Billion in 2023 and is projected to reach US$5.1 Billion by 2030, growing at a CAGR of 6.2% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
The growth in the GPCR market is driven by several factors. Technological advancements have significantly enhanced our understanding of GPCR structures and functions, leading to more targeted and efficient drug development processes. The increasing prevalence of chronic diseases and the need for more effective treatments drive the demand for new GPCR-targeted therapies. Additionally, the pharmaceutical industry`s focus on personalized medicine and the identification of specific GPCRs associated with individual disease states has spurred the development of tailored therapeutic interventions. The expansion of high-throughput screening techniques and computational drug discovery tools has accelerated the identification of potential GPCR modulators. Furthermore, collaborative efforts between academic institutions, biotechnology companies, and pharmaceutical giants have facilitated significant progress in GPCR research and drug development. As the understanding of GPCRs continues to deepen and new technologies emerge, the market for GPCR-targeted therapies is expected to experience robust growth, addressing unmet medical needs and improving patient outcomes across various disease areas.
The growth in the GPCR market is driven by several factors. Technological advancements have significantly enhanced our understanding of GPCR structures and functions, leading to more targeted and efficient drug development processes. The increasing prevalence of chronic diseases and the need for more effective treatments drive the demand for new GPCR-targeted therapies. Additionally, the pharmaceutical industry`s focus on personalized medicine and the identification of specific GPCRs associated with individual disease states has spurred the development of tailored therapeutic interventions. The expansion of high-throughput screening techniques and computational drug discovery tools has accelerated the identification of potential GPCR modulators. Furthermore, collaborative efforts between academic institutions, biotechnology companies, and pharmaceutical giants have facilitated significant progress in GPCR research and drug development. As the understanding of GPCRs continues to deepen and new technologies emerge, the market for GPCR-targeted therapies is expected to experience robust growth, addressing unmet medical needs and improving patient outcomes across various disease areas.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Cell Lines segment, which is expected to reach US$1.9 Billion by 2030 with a CAGR of a 6.1%. The Detection Kits segment is also set to grow at 6.8% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $1.1 Billion in 2023, and China, forecasted to grow at an impressive 8.9% CAGR to reach $416.9 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global G-Protein Coupled Receptors (GPCRs) Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global G-Protein Coupled Receptors (GPCRs) Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global G-Protein Coupled Receptors (GPCRs) Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as Merck KGaA, BD Biosciences, Enzo Life Sciences, Inc., and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 52 Featured):
- Merck KGaA
- BD Biosciences
- Enzo Life Sciences, Inc.
- Lexicon Pharmaceuticals, Inc.
- Molecular Devices LLC
- Aragen Life Sciences Pvt. Ltd.
- Axxam SpA
- Abcam PLC
- Eurofins Scientific SE
- HD Biosciences Co., Ltd.
- Addex Therapeutics
- Multispan, Inc.
- Creative Biolabs
- Beacon Discovery
- Distributed Bio
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYREST OF EUROPEREST OF WORLDIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
Companies Mentioned
- Merck KGaA
- BD Biosciences
- Enzo Life Sciences, Inc.
- Lexicon Pharmaceuticals, Inc.
- Molecular Devices LLC
- Aragen Life Sciences Pvt. Ltd.
- Axxam SpA
- Abcam PLC
- Eurofins Scientific SE
- HD Biosciences Co., Ltd.
- Addex Therapeutics
- Multispan, Inc.
- Creative Biolabs
- Beacon Discovery
- Distributed Bio
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 359 |
Published | November 2024 |
Forecast Period | 2023 - 2030 |
Estimated Market Value ( USD | $ 3.4 Billion |
Forecasted Market Value ( USD | $ 5.1 Billion |
Compound Annual Growth Rate | 6.2% |
Regions Covered | Global |
No. of Companies Mentioned | 15 |